Introduction {#sec0005}
============

First reported in December 2019 in Wuhan District of China, the coronavirus disease 2019 (COVID-19) outbreak has spread all over the world and is a menace to the world community. Birds and wild animals have been suggested as the origin of spread of the causative virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ([@bib0140], [@bib0165]). According to World Health Organization (WHO) statistics from April 12, 2020, a total 1 696 588 confirmed cases of COVID-19 and 105 952 associated deaths had been reported globally ([@bib0135]). Currently no vaccine or effective drug is available for the treatment of this disease, and clinicians are treating patients with neutralizing antibodies against severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) to target the spike protein of this virus ([@bib0010], [@bib0025]). As suggested in recent research, the spike protein, which is present on the surface of SARS-CoV-2, interacts with host targets such as CD26 and ACE2, and is thus considered a potential and logical therapeutic target ([@bib0045], [@bib0155]).

Recent studies have shown the effectiveness of chloroquine against SARS-CoV-2, both in vitro and in clinical trials in China. In addition, some modifications of chloroquine, such as its sulfate and phosphate salts, have also proved beneficial ([@bib0035], [@bib0050], [@bib0125]). However, the US Food and Drug Administration (FDA) has not yet approved this drug for the treatment of COVID-19, and there is a dire need for further clinical trials conducted on geographically different populations to ascertain the effect of this drug.

Human coronaviruses are single-stranded positive-sense RNA viruses comprised of two groups of proteins: (1) structural proteins, which include S (spike) proteins, M (matrix) proteins, N (nucleocapsid) proteins, and E (envelope) proteins, and (2) non-structural proteins, which include proteases such as nsp3 and nsp5, and RdRP such as nsp12. The spike protein is present in homo-trimeric form on the outer surface of the virion particle. Two or three proteases are encoded by the viral RNA, which are potential drug targets against the coronaviruses ([@bib0020], [@bib0115]).

It has been established that the spike protein plays a vital role in attachment and viral entry into the host cell. Moreover, the coronavirus spike protein enters the host cell via angiotensin converting enzyme 2 (ACE2) receptors present on lung epithelial cells and intestinal cells, causing lung disease and diarrhea. The S1 and S2 receptor-binding domain (RBD) of the spike protein attaches to the ACE2 receptor, thus the viral envelope attaches to the membrane and becomes internalized ([@bib0040], [@bib0120]). Another potential target in treating COVID-19 is the main protease enzyme of SARS-CoV-2, considered a central enzyme in regulating viral replication and transcription ([@bib0060]).

This study had two main objectives: to determine the efficacy of antimalarial drugs against SARS-CoV-2 using an in silico approach and to purpose a single potential drug that acts against SARS-CoV-2 spike protein (S1) and also against the catalytic domain of its protease protein.

Methods {#sec0010}
=======

Structure retrieval and pre-processing {#sec0015}
--------------------------------------

The X-ray crystal structure of unliganded protease and the RBD of S1 of the novel SARS-CoV-2 were retrieved from the Protein Data Bank (PDB) repository: ID 6y84 (resolution 1.39 Å) and ID 6vw1 (resolution 2.68 Å), respectively. Both structures were checked for errors and quality using the SAVES server (Structure Analysis and Verification Server). Discovery Studio Visualizer (v19.10.18287, 2019; Dassault Systèmes BIOVIA, San Diego, CA, USA) was used to examine the structural aspects of both proteins, specifically of 6vw1 for the receptor binding residues. After defining the ligand (A chain: angiotensin converting enzyme 2; ACE2) and receptor (E chain: RBD), the interacting residues of the A chain and E chain of 6vw1 were listed for further use in grid generation and docking analysis.

Molecular docking analysis {#sec0020}
--------------------------

### Selection and preparation of ligands {#sec0025}

3D structures of 15 antimalarial drugs ([Table 1](#tbl0005){ref-type="table"} ) were retrieved from the NCBI PubChem compound database (<https://pubchem.ncbi.nlm.nih.gov/>), while 3D structures of 2413 FDA-approved drugs were obtained from DrugBank (<https://www.drugbank.ca/>).Table 1Antimalarial drugs against protease and RBD of SARS-CoV-2.Table 1List of antimalarial drugs testedGlide score\
(Grid for specified residues)Glide score\
(Global docking)Sr. No.NamePubChem CID6y846vw16y846vw11Amodiaquine (flavoquine)2165−4.814−3.211−5.545−4.2002Chloroquine2719−4.111−2.908−4.831−3.8283Primaquine4908−4.165−3.111−5.498−3.6304Pyrimethamine4993−3.634−5.063−5.403−3.6825Halofantrine37393−3.992−3.656−4.765−3.6366(−)-Mefloquine40692−3.940−3.014−4.521−4.5997Artemisinin68827−3.992−2.769−4.162−4.7868Didesethyl chloroquine122672−4.968−3.018−6.296−4.0509Atovaquone74989−3.386−2.394−3.727−3.02410Clindamycin446598−5.558−3.466−5.005−3.86611(*S*)-Chloroquine639540−4.111−2.908−4.831−3.82812Quinine3034034−4.238−2.793−4.491−3.03813Sulfonamides3085933−2.5450.356−3.871−3.62014Proguanil (chloroguanide)6178111−4.127−2.328−1.737−5.12915Doxycycline54671203−5.782−3.749−6.831−4.869[^1]

All ligand compounds were prepared using LigPrep in Schrödinger Maestro 12.2 ([@bib0170]; Schrödinger LLC, New York, NY, USA) using OPLS_2005 force field in Epik mode and applying parameters such as 'generate possible states at target pH' (pH 7), desalting of ligands, and tautomer generation, while retaining specific chiralities to generate at most one per ligand. The general study strategy for the analysis of these ligands is summarized in [Figure 1](#fig0005){ref-type="fig"} .Figure 1Schematic representation of the study.Figure 1

### Protein preparation and Glide docking {#sec0030}

Protein was prepared using the Schrödinger 12.2 Protein Preparation Wizard ([@bib0170]), as described elsewhere ([@bib0110]). Briefly, protein parameters were applied such as the addition of hydrogen atoms, assigning bond orders, creation of zero-order bonds to metal, creation of disulfide bonds, deleting waters beyond 5 Å, and generation of het states using Epik at pH 7. After pre-processing, any already attached ligands were removed and protein structures were corrected if needed by adding side chains and missing atoms, etc., followed by minimization and optimization using OPLS_2005 force field. All of the active site residues of both proteins, including the catalytic dyad and associated residues of 6y84 and RBD residues of 6vw1, were used in receptor grid generation. In the receptor grid, *x*,*y*,*z* coordinates were supplied according to the grid size around the mentioned residues and the grids were generated using default options. Glide molecular docking was conducted under default conditions in extra-precision mode (XP) (Release 2019-4; Schrödinger, LLC). Glide uses a series of scoring functions in XP mode to identify the optimal binding site of the ligand for acceptable poses ([@bib0030]). Top ranked ligands were selected on the basis of the Glide score (in kcal/mol) in order to define the strength of the protein--ligand interaction. Protein residue interactions of docked complexes were visualized and examined in Discovery Studio Visualizer (v19.10.18287, 2019; Dassault Systèmes BIOVIA).

Molecular dynamics simulation {#sec0035}
-----------------------------

Molecular dynamics (MD) simulations of the top-ranked docked complexes were performed using Nano Scale Molecular Dynamics (NAMD); this works with CHARMM++ force field potential functions and parameters ([@bib0105], [@bib0005], [@bib0080]). The topologies and parameter files of proteins and ligand were generated in CHARMM-GUI using PDB Reader and Ligand Reader and Modeler, respectively ([@bib0070], [@bib0065], [@bib0075]). The CHARMM36 force field was applied to protein at a constant number of molecules, volume, and temperature (NVT), and the system was solvated using 'add solvation box' with TIP3p water. Before simulation, each system was first energy-minimized and equilibrated for 200 ps, following which the total energy was observed in multiplot. The energy-minimized systems were subsequently utilized to conduct simulations at constant temperature conditions (310 K) using Langevin dynamics parameters and under constant periodic boundary conditions for 50 ns for comparative trajectory analysis. Visual Molecular Dynamics (VMD 1.9.3) was used to analyze the trajectories and for the post simulation analysis ([@bib0055]).

### Post simulation analysis of trajectories {#sec0040}

The dynamic properties of the complexes in comparison to individual proteins were studied to investigate the stability of the interacting residues. For this purpose, binding energy, root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and per-residue hydrogen bonding interactions were calculated using VMD. The free binding energy was estimated using the Molecular Mechanics Poisson--Boltzmann Surface Area method (MMPBSA) in CaFE1.0 VMD plugin. The net energy of the system was estimated using the following equation ([@bib0090]):

For post simulation analysis, last 1000 continuous frames were extracted without stride. For MMPBSA, data were collected for every 5 ps and the MM (NAMD), PB (APBS), and SA (VMD) values were calculated. In the APBS calculations, the interior dielectric constant was set to 2.0, with exterior dielectric constant as 80 ([@bib0130], [@bib0085]).

Results {#sec0045}
=======

Structural aspects of 6vw1 and 6y84 {#sec0050}
-----------------------------------

The crystal structure of 6vw1 consists of four chains -- A, B, E, and F. Chains A and B belong to the human ACE2 receptor and are identical chains consisting of 571 residues each, while chains E and F belong to the virion and are identical chains comprising 217 residues each. The E chain residues interacting with ACE2 (A chain) include Arg-439, Tyr-449, Tyr-453, Leu-455, Phe-456, Ala-475, Glu-484, Phe-486, Asn-487, Tyr-489, Gln-493, Gly-496, Gln-498, Thr-500, Gly-502, and Tyr-505. In addition, ACE2 (A chain) residues interacting with the SARS-CoV-2 RBD (chain A) include Ser-19, Gln-24, Lys-31, His-34, Glu-35, Glu-37, Asp-38, Tyr-41, Gln-42, Met-82, Tyr-83, Glu-329, Lys-353, and Gly-354 ([Figure 2](#fig0010){ref-type="fig"} ).Figure 2Structural aspects of 6vw1. A: RBD (E chain) of 6VW1 shown in CPK representation while ACE2 (A chain) is shown in line representation. B: Only RBD (E Chain) shown in line representation with active residues in CPK representation.Figure 2

The structure of 6y84 comprises a single chain A of 306 residues, among which two residues are considered as making a catalytic dyad, i.e.; His-41 and Cys-145. Furthermore, some other residues at positions 442, 472, 479, 487, and 491 in the spike protein of SARS-CoV-2 have been reported to play an important role in inter- and intra-species transmission of the virus ([@bib0150]).

Molecular docking analysis of antimalarial drugs {#sec0055}
------------------------------------------------

Fifteen different antimalarial drugs available on the market were docked against 6vw1 and 6y84 adopting two different strategies. In the first strategy, all antimalarial drugs were docked against specific residues (mentioned above) in both proteins, while in the second strategy, the whole protein grid was used to dock each drug for performing blind docking. Glide scores were calculated and were analyzed to check the binding efficiency of these drugs ([Table 1](#tbl0005){ref-type="table"}, Supplemenatry Material Tables S1--S4)

Molecular docking analysis of FDA-approved drugs {#sec0060}
------------------------------------------------

A total of 2413 FDA-approved drugs were used to study potential effective binding against the catalytic site of protease (6y84) and RBD of spike protein (6vw1) (Supplementary Material Tables S5--S10). A distribution plot of docking scores was made for the entire dataset of drugs ([Figure 3](#fig0015){ref-type="fig"} ). Top ranked drugs were selected on the basis of their Glide score ([Table 2](#tbl0010){ref-type="table"} ). The top three drugs against the protease domain were acarbose, colistin, and paromomycin, with Glide scores of −13.139, −12.63, and −11.5.79, respectively. On the other hand, the drugs framycetin, acarbose, and paromomycin showed the highest binding affinity for the RBD with Glide scores of −11.233, −10.49, and −10.01, respectively.Figure 3Distribution plot of docking scores for all the FDA approved drugs\' dataset used.Figure 3Table 2FDA-approved drug showing high binding affinities against protease and RBD of SARS-CoV-2.Table 26y846vw1Drug nameFormulaDrugBank IDGlide scoreDrug nameFormulaDrugBank IDGlide scoreAcarboseC25H43NO18DB00284−13.139FramycetinC23H46N6O13DB00452−11.233ColistinC52H98N16O13DB00803−12.63AcarboseC25H43NO18DB00284−10.649ParomomycinC23H45N5O14DB01421−11.579ParomomycinC23H45N5O14DB01421−10.01IotrolanC37H48I6N6O18DB09487−11.001PlazomicinC25H48N6O10DB12615−9.935Indium In-111 pentetreotideC62H80InN12O19S2DB11835−10.795OmadacyclineC29H40N4O7DB12455−9.178FramycetinC23H46N6O13DB00452−10.713MangafodipirC22H30MnN4O14P2DB06796−9.089Lutetium Lu-177 dotatateC65H87LuN14O19S2DB13985−10.607Flavin adenine dinucleotideC27H33N9O15P2DB03147−8.986RutinC27H30O16DB01698−9.853RibostamycinC17H34N4O10DB03615−8.781[^2]

Tautomeric forms of paromomycin and their docking analysis {#sec0065}
----------------------------------------------------------

There are 11 tautomeric forms of paromomycin (I--XI) due to the alternate protonation state of its amide groups (Supplementary Material Figure S1). To elucidate further, both of the proteins (6y84 and 6vw1) were docked against these 11 tautomeric forms (Supplementary Material Tables S11 and S12). It was observed that both proteins gave the highest Glide score for form I. It was clear from the results that paromomycin I exhibits the highest binding affinity against SARS-CoV-2. Thus, these docked complexes of both proteins with paromomycin I were further utilized for MD simulation.

The 2D diagrams from ligand--protein interactions of docked complexes were evaluated to examine the residues involved in binding with paromomycin I. In the 2D diagram of the 6vw1--ligand complex, a total of seven hydrogen bonds, two salt bridges, five carbon--hydrogen bonds, and a few van der Waals interactions were observed ([Figure 4](#fig0020){ref-type="fig"}A). Residues involved in the different interaction types include Lys-403, Asp-405, Asp-406, Arg-408, Gln-409, Ile-418, Tyr-453, Gln-493, Ser-494, Tyr-495, Gly-496, Phe-497, and Tyr-505. [Figure 4](#fig0020){ref-type="fig"}. It was further observed that protease (6y84) showed a total of nine hydrogen bonds, two salt bridges, and three carbon--hydrogen bonds with a few van der Waals interactions with paromomycin I (Figure 4B). It was clearly depicted from the interaction diagram that Cys-145 makes a strong hydrogen bond with the protonated amide group of paromomycin I, while His-41 exhibits van der Waals interactions in close proximity. Besides these two catalytic residues, Glu-166 makes two hydrogen bonds, two salt bridges, and one carbon--hydrogen bond. Other residues in the interaction diagram are Leu-27, Phe-140, Leu-141, Asn-142, Ser-144, His-163, Met-165.Figure 42D diagram of (A) 6vw1-liagnd (complex-1) and (B) 6y84-ligand (complex-2).Figure 4

Docking analysis of acarbose with target proteins {#sec0070}
-------------------------------------------------

Acarbose is another common drug that showed strong binding affinity for both targets, i.e. 6y84 =−13.139 kcal/mol; 6vw1 = −10.649 kcal/mol ([Table 2](#tbl0010){ref-type="table"}). Acarbose made a total of 13 hydrogen bonds, one carbon--hydrogen bond, and also some van der Waals interactions with 6vw1 in docked complex 3 ([Figure 5](#fig0025){ref-type="fig"} A). The interacting residues are Lys-403, Asp-406, Gln-409, Tyr-453, Gln-493, Tyr-495, Gly-496, Phe-497, Asn-501, and Tyr-505. In the case of 6y84, acarbose forms 10 hydrogen bonds, one carbon--hydrogen bond, one alkyl bond, and other non-covalent interactions in complex 4 ([Figure 5](#fig0025){ref-type="fig"}B). Residues involved in these interactions are as follow: Thr-26, His-41, Ser-46, Met-49, Leu-141, Asn-142, Ser-144, Cys-145, His-164, Met-165, Glu-166, Pro-168, Arg-188, Gln-189, Thr-190, and Gln-192.Figure 52D diagram of (A) 6vw1-ligand (Complex-3) and (B) 6y84-ligand (Complex-4).Figure 5

Stability of complexes by MD analysis {#sec0075}
-------------------------------------

### Molecular Mechanics Poisson--Boltzmann Surface Area method (MMPBSA) {#sec0080}

MD simulation of complex 1 (6vw1--ligand) and complex 2 (6y84--ligand) along with individual proteins without ligands (6vw1: protein-1; 6y84: protein-2) was conducted to record the trajectories for 50 ns. The MMPBSA model was generated using CaFE1.0 VMD plugin. The net binding energy for complex 1 and complex 2 were found to be −18.3624 kcal/mol and −234.0711 kcal/mol, respectively, showing both complexes to be stable ([Table 3](#tbl0015){ref-type="table"} ). The stability of complex 1 is favored by electrostatic (−25.7727 kcal/mol), van der Waals (−18.0870 kcal/mol), and non-polar energies (−22.0747 kcal/mol). In the case of complex 2, the net binding energy is highly contributed by electrostatic energy (−451.4246 kcal/mol) and less by van der Waals (−37.7393 kcal/mol).Table 3MMPBSA model for complex 1 and complex 2.Table 3MMPBSA modelComplex 1Complex 2Elec−25.7727 ± 14.0375−451.4246 ± 16.3534Vdw−18.0870 ± 2.9519−37.7393 ± 3.4501PB29.4849 ± 6.9718261.2760 ± 8.1962SA−3.9877 ± 0.1210−6.1831 ± 0.1261Gas−43.8596 ± 13.5039−489.1639 ± 16.2019Sol25.4972 ± 6.9007255.0928 ± 8.1390Pol3.7122 ± 8.5699−190.1487 ± 9.4145Npol−22.0747 ± 2.9860−43.9224 ± 3.4572ΔG~bind~−18.3624 ± 7.5918−234.0711 ± 8.9385[^3]

### RMSD and RMSF calculations {#sec0085}

In order to determine time-dependent conformational changes, RMSD analysis was performed in the RMSD trajectory tool of VMD. RMSD graphs were generated with respect to 5000 frames (50 ns) using the backbone of their initial structures as reference. The average RMSD of complex 1 was found to be 1.413 ± 0.180 Å, while the average RMSD of protein-1 was calculated to be 1.245 ± 0.140 Å. It was observed that the maximum RMSD value never exceeded 1.8 Å during simulation, which means that complex 1 remained stable for the entire simulation period. For complex 1, the RMSD gradually increased up until 28 ns, with a drift at 30 ns suggesting some structural changes, but the complex remained stable and converged after 35 ns ([Figure 6](#fig0030){ref-type="fig"} A). For complex 2, the average RMSD was calculated as 1.150 ± 0.157 Å, while the average RMSD of protein-2 was calculated to be 1.443 ± 0.280 Å. Complex 2 was also found to be stable, as maximum RMSD never exceeded 2 Å for the entire simulation period. In the case of complex 2, the RMSD value increased up until 32 ns and converged afterwards, with minor fluctuations ([Figure 6](#fig0030){ref-type="fig"}B).Figure 6RMSD plot. (A) Complex-1 in comparison to Protein-1 and (B) Complex-2 in comparison to Protein-2.Figure 6

Per residue RMSFs were calculated for the last 1000 frames in the timeline plugin of VMD using a comparative approach ([Figure 7](#fig0035){ref-type="fig"} ). In the case of complex 1, the binding pocket region (residues 400--505) was divided into three interacting regions: (1) residues 403--418, (2) residues 453--455, and (3) residues 493--505. In the first region of complex 1, Pro-412 (0.39/0.27 Å, complex 1/protein-1) and Gly-413 (0.38/0.17 Å, complex 1/protein-1) showed drift in RMSF values that could be due to two hydrogen bond formations by Asp-406 and Gln-409 with the ligand in this region. In region 2, Arg-454 and Leu-455 showed higher RMSFs than protein-1, possibly due to the contribution of two hydrogen bonds by Tyr-453 and van der Waals interactions by Leu-455. Prior to region 3, Pro-492 exhibited very much higher fluctuation in complex 1 (0.41 Å) in addition to Ser-494 (0.21 Å) and Thr-500 (0.36 Å) inside the region in comparison to the respective positions in protein-1. All other interacting residues, except those mentioned above, had comparable or even lower fluctuations as compared to unliganded protein. The lower RMSF values of these residues could be related to the rigidity of these residues for any motion due to the presence of the ligand that contributes stability and loss of flexibility ([@bib0015]). In the case of complex 2, four interacting regions were found: (1) residues 140--146, (2) residues 163--168, (3) residues 25--27, and (4) residues 41--49. In region 1, Cys-145 showed higher fluctuation in complex 2 (0.3 Å) than in protein-2 (0.25 Å). Glu-166 did not show any prominent variation in complex 2, but its neighboring residues Met-165 and Leu-167 had higher residual fluctuations. Regions 3 and 4 contributed through van der Waals interactions with the ligand and showed no major residual fluctuations. Overall, both of the complexes exhibited lower RMSF values, referring to less motion in the binding region and conferring their stability.Figure 7Comparative RMSF plot of (A) complex-1 and protein-1; and (B) complex-2 and protein-2.Figure 7

### Hydrogen bond interactions {#sec0090}

The hydrogen bond interactions of the complexes were calculated to validate affinity of the ligand to inhibit the proteins predicted by the docking simulation studies. For this purpose, two strategies were adopted. In the first strategy, the total number of hydrogens in the complexes and proteins were examined for comparative purposes ([Figure 8](#fig0040){ref-type="fig"} ). Based on the result, complex 2 had a higher number of hydrogen atoms than protein-1, while complex 1 and protein-1 exhibited almost comparable hydrogen bonds. In the second strategy, the number of hydrogen bonds between the receptor and ligand in complexes (acceptor/donor) were calculated and matched for identity with the hydrogen bond residues predicted in the docking analysis ([Table 4](#tbl0020){ref-type="table"} ). It was confirmed that the residues involved in hydrogen bonding during post simulation analysis of trajectories were the same residues contributing to hydrogen bonding during the docking analysis.Figure 8Total hydrogen bonds during the time course of MD simulation.Figure 8Table 4Total hydrogen bonds between receptor and ligand determined from MD trajectories.Table 4Complex 1Complex 2DonorAcceptorDonorAcceptorUNK900-SideAsp406-SideUNK1-SideGlu166-MainTyr505-SideUNK900-SideUNK1-SideGluU166-SideUNK900-SideGln09-SideGlu166-MainUNK1-SideTyr453-SideUNK900-SideAsn142-SideUNK1-SideGln409-SideUNK900-SideUNK1-SideAsn142-SideUNK1-SidePhe140-MainUNK1-SideGln189-SideUNK1-SideCys145-SideUNK1-SideSer46-SideUNK1-SideLeu141-MainGln189-SideUNK1-SideUNK1-SideSer144-SideUNK1-SideThr25-SideUNK1-SideHis41-Side[^4]

Discussion {#sec0095}
==========

In this study, it was observed that none of the antimalarial drugs showed strong binding affinity with the active sites of either protease or the RBD. Considering the novelty of the virus, blind docking was performed with antimalarial drugs for further elucidation. Again, no significant binding was observed, as evident from the Glide scores ([Table 1](#tbl0005){ref-type="table"}; Supplementary Material Tables S1--S4). This study confirmed that no antimalarial drug shows strong binding affinity for SARS-CoV-2 using molecular docking analysis.

Molecular docking analysis of FDA-approved drugs showed that paromomycin could bind both protease and RBD effectively, so it was selected for subsequent studies. Previous studies have used a single target approach for targeting coronavirus, either using protease or spike protein (RBD) as the target ([@bib0100], [@bib0145]). In the present study, both the catalytic and RBD domains were targeted side by side using a single drug, i.e. paromomycin. This dual targeted approach could have many advantages over a single target approach. The potential benefit of this strategy is that it may keep the virus from binding to the receptor (ACE2) and at the same time halt replication of the virus by binding to the catalytic domain of protease.

In the catalytic domain, paromomycin not only interacts with His-41 and Cys-145, but also with Glu-166. Besides the two key catalytic residues, Glu-166 is also considered to play a central role in maintaining the shape of the protease (S1) catalytic pocket, rendering it in active form ([@bib0160]). Further analysis of complex 2 using MD validated its stability. It is also evident from the binding energies of complex 2 that it is highly stable in the presence of the ligand. Further validation of high binding energy was supported by the hydrogen bond analysis of MD trajectories. Complex 2 showed 14 hydrogen bonds between the ligand and protease, which is well supported by the values of free binding energy.

In the case of spike protein, complex 1 showed strong binding affinity with the said residues. Some residues such as Asn-439, Asn-501, Gln-493, Gly-485, Phe-486, Arg-408, Gln-409, Thr-445, Val-417, Leu-461, Asp-467, Ser-469, Leu-491, Asn-492, Asp-493, Tyyr-494, Thr-497, Thr-150, and Tyr-504 are also considered important during interaction with receptors (ACE2 and CD26) ([@bib0095], [@bib0115]). So these residues must also be taken into account when suggesting a drug targeting the RBD. In this study, the paromomycin binding site with RBD showed interactions involving many of these residues. Overall, the binding energy and the number of hydrogen bonds in complex 1 were lower than those in complex 2, but it still showed good stability in the presence of ligand and can be considered well inhibited by it.

In addition to paromomycin, acarbose, an anti-diabetic drug, was also found to show strong binding affinity for both target proteins. As this drug is used for the diabetic population, we propose that it could be tested at the clinical level in diabetic patients suffering from COVID-19.

Paromomycin, a broad-spectrum aminoglycoside antimicrobial that was originally used to treat acute and chronic intestinal infections, may also be of potential use to treat COVID-19. We propose that paromomycin should be tested to reposition its therapeutic target for the treatment of COVID-19.
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[^1]: RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

[^2]: FDA, US Food and Drug Administration; RBD, receptor-binding domain; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

[^3]: MMPBSA, Molecular Mechanics Poisson--Boltzmann Surface Are

[^4]: MD, molecular dynamics.
